Halozyme Therapeutics Competitors and Similar CompaniesClear all

Halozyme Therapeutics's competitors and similar companies include Karyopharm Therapeutics, Verastem Oncology, Blueprint Medicines, Partner Therapeutics and Rakuten Medical.
Halozyme Therapeutics
Halozyme Therapeutics
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
Karyopharm Therapeutics
Karyopharm Therapeutics
Karyopharm Therapeutics is a pharmaceutical company that discovers and develops drugs for the treatment of cancer and other major diseases.
Verastem Oncology
Verastem Oncology
Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.
Blueprint Medicines
Blueprint Medicines
Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.
Partner Therapeutics
Partner Therapeutics
Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.
Rakuten Medical
Rakuten Medical
Rakuten Medical (formerly Rakuten Aspyrian) is a clinical stage biotechnology company developing tumor-targeted precision therapies.
Founding Date
Founding Date
1998
Founding Date
2008
Founding Date
2010
Founding Date
2011
Founding Date
2017
Founding Date
2013
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Private
Type
Private
Tags
Locations
Locations
San Diego, US HQ
Locations
Newton, US HQ
Munich, DE
Giv'atayim, IL
Locations
Needham, US HQ
Walsrode, DE
Locations
Cambridge, US HQ
Amsterdam, NL
Lugano, CH
Zug, CH
Locations
Lexington, US HQ
Boston, US
Lynnwood, US
Locations
San Diego, US HQ
Setagaya City, JP
Amsterdam, NL
Ecublens, CH
Taipei, TW
Taipei, TW
San Mateo, US
Employees
Employees
1457% increase
Employees
38521% decrease
Employees
5719% increase
Employees
49515% increase
Employees
2051% decrease
Employees
1331% decrease
Valuation ($)
Valuation ($)
4.6 b
Valuation ($)
155.8 m
Valuation ($)
314.6 m
Valuation ($)
5.5 b
Valuation ($)
N/A
Valuation ($)
N/A
Twitter followers
Twitter followers
423
Twitter followers
1.5 k
Twitter followers
2.6 k
Twitter followers
2.8 k
Twitter followers
147
Twitter followers
N/A
Number of tweets (last 30 days)
Number of tweets (last 30 days)
9
Number of tweets (last 30 days)
6
Number of tweets (last 30 days)
6
Number of tweets (last 30 days)
3
Number of tweets (last 30 days)
2
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
1.8
Average likes per tweet (last 30 days)
3.2
Average likes per tweet (last 30 days)
4
Average likes per tweet (last 30 days)
3.7
Average likes per tweet (last 30 days)
1.5
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
88.89%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Employee Rating
Employee Rating
3.1
Employee Rating
3.7
Employee Rating
4.3
Employee Rating
4.2
Employee Rating
4.4
Employee Rating
2.1

Financial

Revenue (est.)
Revenue (est.)
$660.1m (FY, 2022)
Revenue (est.)
$157.1m (FY, 2022)
Revenue (est.)
$2.6m (FY, 2022)
Revenue (est.)
$249.4m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
N/A
Cost of goods
Cost of goods
$139.3m (FY, 2022)
Cost of goods
N/A
Cost of goods
N/A
Cost of goods
$8.5m (FY, 2023)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
$520.8m (FY, 2022)
Gross profit
N/A
Gross profit
N/A
Gross profit
$240.8m (FY, 2023)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
$202.1m (FY, 2022)
Net income
($165.3m) (FY, 2022)
Net income
($73.8m) (FY, 2022)
Net income
($507m) (FY, 2023)
Net income
N/A
Net income
N/A

Operating

Phase II Trials Products
Phase II Trials Products
1 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2020)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A

Funding

Latest funding round
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
N/A
Latest funding round
$ 60m (about 6 years ago)
Latest funding round
$ 100m (over 4 years ago)
Total funding raised
Total funding raised
$ 171.9m
Total funding raised
$ 248.7m
Total funding raised
$ 170m
Total funding raised
$ 1.7b
Total funding raised
$ 60m
Total funding raised
$ 451.9m
For sources of this data, please see the company profile

View Company Profiles

Karyopharm Therapeutics
HQ
Newton, US
Employees
385↓ 21% decrease

Karyopharm Therapeutics is a pharmaceutical company that discovers and develops drugs for the treatment of cancer and other major diseases.

View company
Verastem Oncology
HQ
Needham, US
Employees
57↑ 19% increase

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer.

View company
Blueprint Medicines
HQ
Cambridge, US
Employees
495↑ 15% increase

Blueprint Medicines is a precision therapy company that invents medicines for people with cancer and blood disorders.

View company
Partner Therapeutics
HQ
Lexington, US
Employees
205↓ 1% decrease

Partner Therapeutics is developing and commercializing cancer medicines and combination therapies.

View company